Healthy Skepticism Library item: 6126
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Timmermans AE.
[Misleading advertisement on Opatanol].
Ned Tijdschr Geneeskd 2006 Jul 1; 150:(26):1472
Abstract:
In an advertisement in this journal, Alcon Nederland BV has recommended Opatanol (olopatadin) as the ‘first choice medication/NHG practice guideline for Red eye/Allergic conjunctivitis’. However, the practice guideline of the Dutch College of General Practitioners (NHG) mentions the following 3 antihistaminica as first choice for the treatment of red eye/allergic conjunctivitis: azelastin, levocabastin or olopatadin. Therefore, it is concluded that the Alcon advertisement is misleading.
Keywords:
Advertising*
Anti-Allergic Agents/therapeutic use*
Conjunctivitis, Allergic/drug therapy*
Dibenzoxepins/therapeutic use*
English Abstract
Histamine H1 Antagonists/therapeutic use*
Humans
Netherlands
Practice Guidelines*
